[go: up one dir, main page]

WO2014153117A3 - Antibodies to hgf and compositions containing - Google Patents

Antibodies to hgf and compositions containing Download PDF

Info

Publication number
WO2014153117A3
WO2014153117A3 PCT/US2014/029163 US2014029163W WO2014153117A3 WO 2014153117 A3 WO2014153117 A3 WO 2014153117A3 US 2014029163 W US2014029163 W US 2014029163W WO 2014153117 A3 WO2014153117 A3 WO 2014153117A3
Authority
WO
WIPO (PCT)
Prior art keywords
hgf
antibodies
binding fragments
compositions containing
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/029163
Other languages
French (fr)
Other versions
WO2014153117A9 (en
WO2014153117A2 (en
Inventor
Benjamin H. Dutzar
Katie ANDERSON
Brian R. Kovacevich
Andrew L. Feldhaus
John A. Latham
Leon F. GARCIA-MARTINEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Seattle Biopharmaceuticals Inc
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Priority to KR1020157029279A priority Critical patent/KR20150140685A/en
Priority to CN201480026978.3A priority patent/CN105246915A/en
Priority to JP2016503002A priority patent/JP2016516052A/en
Priority to CA2904743A priority patent/CA2904743A1/en
Priority to EP14767985.6A priority patent/EP2964673A4/en
Publication of WO2014153117A2 publication Critical patent/WO2014153117A2/en
Publication of WO2014153117A9 publication Critical patent/WO2014153117A9/en
Publication of WO2014153117A3 publication Critical patent/WO2014153117A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.
PCT/US2014/029163 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing Ceased WO2014153117A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020157029279A KR20150140685A (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing
CN201480026978.3A CN105246915A (en) 2013-03-14 2014-03-14 Antibodies to HGF and Compositions Containing
JP2016503002A JP2016516052A (en) 2013-03-14 2014-03-14 Antibodies against HGF and compositions containing them
CA2904743A CA2904743A1 (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing
EP14767985.6A EP2964673A4 (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361782868P 2013-03-14 2013-03-14
US201361781643P 2013-03-14 2013-03-14
US61/782,868 2013-03-14
US61/781,643 2013-03-14

Publications (3)

Publication Number Publication Date
WO2014153117A2 WO2014153117A2 (en) 2014-09-25
WO2014153117A9 WO2014153117A9 (en) 2014-11-27
WO2014153117A3 true WO2014153117A3 (en) 2015-01-08

Family

ID=51581767

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/029383 Ceased WO2014153166A2 (en) 2013-03-14 2014-03-14 Therapeutic use of antibodies to hgf
PCT/US2014/029163 Ceased WO2014153117A2 (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029383 Ceased WO2014153166A2 (en) 2013-03-14 2014-03-14 Therapeutic use of antibodies to hgf

Country Status (7)

Country Link
EP (1) EP2964673A4 (en)
JP (1) JP2016516052A (en)
KR (1) KR20150140685A (en)
CN (1) CN105246915A (en)
CA (1) CA2904743A1 (en)
TW (2) TW201438737A (en)
WO (2) WO2014153166A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868B (en) * 2017-03-01 2019-11-15 牡丹江医学院 A protein and the nucleotide sequence encoding it
CN109771642B (en) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET agonistic antibodies and uses thereof
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN121197419A (en) * 2019-09-30 2025-12-26 上海生物制品研究所有限责任公司 Use of peginterferon and protooncogene product targeted inhibitors in synergistic treatment of renal cancer
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
WO2022228514A1 (en) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 Anti-human leukemia inhibitory factor antibody and use thereof
WO2024129564A1 (en) * 2022-12-13 2024-06-20 The Children's Medical Center Corporation Methods and compositions for the treatment of vascular anomalies
KR20250058158A (en) * 2023-10-20 2025-04-30 주식회사 셀랩메드 A pharmaceutical composition for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718174B2 (en) * 2006-07-14 2010-05-18 Abxign, Inc. Anti-HGF/SF humanized antibody
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof
US20130344068A1 (en) * 2010-12-01 2013-12-26 Leon F. Garcia-Martinez Methods of preventing inflammation and treating pain using anti-ngf compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
BRPI0412885A (en) * 2003-07-18 2006-10-03 Amgen Inc polypeptides, specific binding agents, nucleic acid molecules and isolated cell lines, host cells, compositions and antigen binding domain or antibody and methods of treating cancer and solid tumor in a patient, detecting growth factor level hepatocyte (hgf) in a sample, obtaining antibody and inhibiting hgf binding to met and decreasing or preventing the binding of any of the hepatocyte growth factor (hgf) -specific binding agents
AR059922A1 (en) * 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
NZ572807A (en) * 2006-05-19 2011-10-28 Alder Biopharmaceuticals Inc Culture method for obtaining a clonal population of antigen-specific b cells
EP2380908A1 (en) * 2006-06-02 2011-10-26 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
SG158112A1 (en) * 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
SI2027156T1 (en) * 2006-06-02 2011-05-31 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718174B2 (en) * 2006-07-14 2010-05-18 Abxign, Inc. Anti-HGF/SF humanized antibody
US20100129357A1 (en) * 2008-11-25 2010-05-27 Leon Garcia-Martinez Antibodies to il-6 and use thereof
US20130344068A1 (en) * 2010-12-01 2013-12-26 Leon F. Garcia-Martinez Methods of preventing inflammation and treating pain using anti-ngf compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURGESS ET AL.: "Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors'.", CANCER RESEARCH, vol. 66, 1 February 2006 (2006-02-01), pages 1721 - 1729, XP008075112 *
See also references of EP2964673A4 *

Also Published As

Publication number Publication date
JP2016516052A (en) 2016-06-02
WO2014153166A3 (en) 2014-12-04
WO2014153166A2 (en) 2014-09-25
TW201444868A (en) 2014-12-01
CA2904743A1 (en) 2014-09-25
KR20150140685A (en) 2015-12-16
CN105246915A (en) 2016-01-13
EP2964673A4 (en) 2017-02-22
WO2014153117A9 (en) 2014-11-27
WO2014153117A2 (en) 2014-09-25
EP2964673A2 (en) 2016-01-13
TW201438737A (en) 2014-10-16

Similar Documents

Publication Publication Date Title
PH12018500521A1 (en) Anti-cgrp compositions and use thereof
NZ702304A (en) Anti-pcsk9 antibodies and use thereof
WO2012075340A3 (en) Anti-ngf compositions and use thereof
WO2014153117A3 (en) Antibodies to hgf and compositions containing
WO2008144753A3 (en) Antibodies to tnf alpha and use thereof
EP4640706A3 (en) Humanized anti-pacap antibodies and uses thereof
WO2015053871A3 (en) NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
BR112015009961A2 (en) anti-vegf / dll4 double domain variable immunoglobulins and use of these
WO2015073580A8 (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2016100838A3 (en) Humanized anti-acth antibodies and use thereof
WO2011025964A3 (en) Therapeutic dll4 binding proteins
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012005037A (en) Dual variable domain immunoglobulins and uses thereof.
MX2012001262A (en) Dual variable domain immunoglobulins and uses thereof.
MX2011011669A (en) Dual variable domain immunoglobulins and uses thereof.
HK1212711A1 (en) Bcma antigen binding proteins
WO2014144280A8 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
MX2009012492A (en) Antibodies to il-6 and use thereof.
WO2013101972A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2011050262A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2012080926A3 (en) Anti-notch1 antibodies
WO2009105585A3 (en) Postsynaptically targeted chemodenervation agents and their methods of use
WO2015187811A3 (en) Human monoclonal antibodies to ganglioside gd2
WO2011040973A3 (en) Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14767985

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2904743

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016503002

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014767985

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157029279

Country of ref document: KR

Kind code of ref document: A